CO6801734A2 - Derivados de etinilo como moduladores alostéricos positivos de mglur5 - Google Patents
Derivados de etinilo como moduladores alostéricos positivos de mglur5Info
- Publication number
- CO6801734A2 CO6801734A2 CO13205214A CO13205214A CO6801734A2 CO 6801734 A2 CO6801734 A2 CO 6801734A2 CO 13205214 A CO13205214 A CO 13205214A CO 13205214 A CO13205214 A CO 13205214A CO 6801734 A2 CO6801734 A2 CO 6801734A2
- Authority
- CO
- Colombia
- Prior art keywords
- hydrogen
- res
- lower alkyl
- mglur5
- positive allosteric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P70/00—Climate change mitigation technologies in the production process for final industrial or consumer products
- Y02P70/50—Manufacturing or production processes characterised by the final manufactured product
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
- Y02T10/00—Road transport of goods or passengers
- Y02T10/60—Other road transportation technologies with climate change mitigation effect
- Y02T10/70—Energy storage systems for electromobility, e.g. batteries
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Secondary Cells (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Liquid Crystal Substances (AREA)
Abstract
La presente invención se refiere a derivados de etinilo de la fórmula I X es N o C-R, dicho R es hidrógeno o halógeno;G es N o CH; con la condición de que como máximo uno de G o X pueda ser nitrógeno;Res fenilo o piridinilo, que están opcionalmente sustituidos por halógeno;Res hidrógeno, alquilo inferior, hidroxi, alcoxi inferior o C(O)O-bencilo;R, R, R, R, R, Rcon independencia entre sí son hidrógeno o alquilo inferior; o Ry Rjunto con el átomo de carbono al que están unidos pueden formar un anillo cicloalquilo C, si m es el número 0 y n es el número 1 ó 2;Res hidrógeno o alquilo inferior;n es el número 0, 1 ó 2;m es el número 0 ó 1; con la condición de que n y m no sean simultáneamente el número 0; o a una sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica, o a su enatiómero correspondiente y/o isómero óptico y/o estereoisómero de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11163683 | 2011-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6801734A2 true CO6801734A2 (es) | 2013-11-29 |
Family
ID=46025665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13205214A CO6801734A2 (es) | 2011-04-26 | 2013-08-29 | Derivados de etinilo como moduladores alostéricos positivos de mglur5 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8957213B2 (es) |
| EP (1) | EP2702051B1 (es) |
| JP (1) | JP5753627B2 (es) |
| KR (1) | KR101554803B1 (es) |
| CN (1) | CN103492373B (es) |
| AR (1) | AR086036A1 (es) |
| AU (1) | AU2012247653B2 (es) |
| BR (1) | BR112013026116A2 (es) |
| CA (1) | CA2829170C (es) |
| CL (1) | CL2013003056A1 (es) |
| CO (1) | CO6801734A2 (es) |
| CR (1) | CR20130475A (es) |
| CY (1) | CY1116391T1 (es) |
| DK (1) | DK2702051T3 (es) |
| EA (1) | EA022019B1 (es) |
| ES (1) | ES2534090T3 (es) |
| HK (1) | HK1191330A1 (es) |
| HR (1) | HRP20150555T1 (es) |
| HU (1) | HUE025031T2 (es) |
| IL (1) | IL228835A (es) |
| MA (1) | MA35133B1 (es) |
| MX (1) | MX337443B (es) |
| MY (1) | MY163164A (es) |
| PE (1) | PE20141169A1 (es) |
| PL (1) | PL2702051T3 (es) |
| PT (1) | PT2702051E (es) |
| RS (1) | RS53903B1 (es) |
| SG (1) | SG194120A1 (es) |
| SI (1) | SI2702051T1 (es) |
| TW (2) | TW201306355A (es) |
| UA (1) | UA110378C2 (es) |
| WO (1) | WO2012146551A1 (es) |
| ZA (1) | ZA201306586B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE025031T2 (en) * | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
| UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| SI2875000T1 (sl) * | 2012-07-17 | 2017-01-31 | F.Hoffmann-La Roche Ag | Ariletinilni derivati |
| NZ703537A (en) * | 2012-10-18 | 2018-06-29 | Hoffmann La Roche | Ethynyl derivatives |
| UA116023C2 (uk) * | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| CN107849006B (zh) | 2015-06-03 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
| CN107580598B (zh) | 2015-07-15 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体调节剂的乙炔基衍生物 |
| US10423423B2 (en) * | 2015-09-29 | 2019-09-24 | International Business Machines Corporation | Efficiently managing speculative finish tracking and error handling for load instructions |
| PE20190382A1 (es) | 2016-07-18 | 2019-03-08 | Hoffmann La Roche | Derivados etinilo |
| AU2018347349A1 (en) * | 2017-10-10 | 2020-04-23 | Biogen Inc. | Process for preparing spiro derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EP2380889B1 (en) * | 2004-10-07 | 2013-06-26 | Merck Sharp & Dohme Corp. | Thiazolyl MGLUR5 antagonists and methods for their use |
| EP1809620B1 (en) | 2004-11-04 | 2010-12-29 | Addex Pharma SA | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| WO2007137954A1 (en) | 2006-05-31 | 2007-12-06 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
| WO2008151184A1 (en) * | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| US8034806B2 (en) * | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
| TW201020245A (en) | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| HUE025031T2 (en) * | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
-
2012
- 2012-04-23 HU HUE12718153A patent/HUE025031T2/en unknown
- 2012-04-23 AU AU2012247653A patent/AU2012247653B2/en not_active Ceased
- 2012-04-23 CN CN201280019903.3A patent/CN103492373B/zh active Active
- 2012-04-23 RS RS20150192A patent/RS53903B1/en unknown
- 2012-04-23 ES ES12718153.5T patent/ES2534090T3/es active Active
- 2012-04-23 KR KR1020137031119A patent/KR101554803B1/ko active IP Right Grant
- 2012-04-23 JP JP2014506826A patent/JP5753627B2/ja active Active
- 2012-04-23 SG SG2013074810A patent/SG194120A1/en unknown
- 2012-04-23 PL PL12718153T patent/PL2702051T3/pl unknown
- 2012-04-23 BR BR112013026116A patent/BR112013026116A2/pt not_active IP Right Cessation
- 2012-04-23 MY MYPI2013003846A patent/MY163164A/en unknown
- 2012-04-23 PT PT127181535T patent/PT2702051E/pt unknown
- 2012-04-23 SI SI201230199T patent/SI2702051T1/sl unknown
- 2012-04-23 EP EP20120718153 patent/EP2702051B1/en active Active
- 2012-04-23 UA UAA201313475A patent/UA110378C2/uk unknown
- 2012-04-23 US US13/452,973 patent/US8957213B2/en active Active
- 2012-04-23 EA EA201391537A patent/EA022019B1/ru not_active IP Right Cessation
- 2012-04-23 CA CA2829170A patent/CA2829170C/en not_active Expired - Fee Related
- 2012-04-23 MX MX2013011105A patent/MX337443B/es active IP Right Grant
- 2012-04-23 WO PCT/EP2012/057335 patent/WO2012146551A1/en active Application Filing
- 2012-04-23 PE PE2013002401A patent/PE20141169A1/es active IP Right Grant
- 2012-04-23 DK DK12718153T patent/DK2702051T3/en active
- 2012-04-24 AR ARP120101405 patent/AR086036A1/es unknown
- 2012-04-24 TW TW101114538A patent/TW201306355A/zh unknown
- 2012-04-24 TW TW101114577A patent/TWI436993B/zh not_active IP Right Cessation
-
2013
- 2013-08-29 CO CO13205214A patent/CO6801734A2/es active IP Right Grant
- 2013-09-02 ZA ZA2013/06586A patent/ZA201306586B/en unknown
- 2013-09-23 CR CR20130475A patent/CR20130475A/es unknown
- 2013-10-10 IL IL228835A patent/IL228835A/en active IP Right Grant
- 2013-10-22 CL CL2013003056A patent/CL2013003056A1/es unknown
- 2013-11-22 MA MA36462A patent/MA35133B1/fr unknown
-
2014
- 2014-05-09 HK HK14104405.5A patent/HK1191330A1/xx unknown
-
2015
- 2015-01-06 US US14/590,530 patent/US9212171B2/en active Active
- 2015-05-20 CY CY20151100452T patent/CY1116391T1/el unknown
- 2015-05-26 HR HRP20150555TT patent/HRP20150555T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6801734A2 (es) | Derivados de etinilo como moduladores alostéricos positivos de mglur5 | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| ECSP14013296A (es) | Derivados de etinilo | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| CO6741199A2 (es) | \"5-(fenil/piridinil-etinil)-2-piridina/ 2-pirimidina-caboxamidas como moduladores del receptor mglur5\" | |
| EA201691046A1 (ru) | Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| ES2572052T3 (es) | Amidas macrocíclicas como inhibidores de proteasas | |
| AR086113A1 (es) | Isoxazolinas como agentes terapeuticos | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| CO6801735A2 (es) | Derivados de pirazolidin-3-ona | |
| CY1117212T1 (el) | Εθυνυλο παραγωγα ως μεταβοτροπικοι ρυθμιστες του υποδοχεα γλουταμινικου | |
| AR080102A1 (es) | Compuestos de aril-bencil-amina y su utilizacion en el tratamiento de trastornos mediados por las interacciones de los linfocitos | |
| AR078672A1 (es) | Derivados de dihidropirrolonaftiridinonas inhibidores de quinasas jak, composiciones farmaceuticas que los contienen y uso de los mismos para tratar procesos inmunologicos, canceres y otras patologias. | |
| EA201390857A1 (ru) | Анальгезирующие соединения, способы и составы | |
| AR080081A1 (es) | Derivados de tetrahidropirano | |
| AR095940A1 (es) | Inhibidores de la phd de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida | |
| CR20120614A (es) | Derivados de amino-tropano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |